SAKK Cancer oncology clinical trial

• Forschungsstelle: SIAK
• Projektnummer: SAKK 35/98
• Projekttitel Englisch: A randomized phase III trial to determine the effect of consolidation with rituximab (IDEC C2B8 Mabthera) in patients with CD20+ follicular or mantle cell lymphoma having received induction therapy with rituximab weekly x 4

Schlüsselwörter (Englisch)

SAKK Cancer oncology clinical trial Lymphoma CD20+ Rituximab Mabthera

Kurzbeschreibung (Englisch)

A randomized phase III trial to determine the effect of consolidation with rituximab (IDEC C2B8 Mabthera) in patients with CD20+ follicular or mantle cell lymphoma having received induction therapy with rituximab weekly x 4

Umsetzung und Anwendungen (Englisch)

Basis for evidence based oncological treatment

Publikationen / Ergebnisse (Englisch)

first publication: annales of Oncology 11 (Suppl.1) : 123-126, 2000

Zugehörige Dokumente

• M. Ghielmini et al.: Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK), Annals of Oncology 16: 1675–1682, 2005. [PDF] 192 kB

URL-Adressen (Englisch)

http://www.siak.ch